We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-17.58%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$221M
AUM Growth
-$96.8M
Cap. Flow
-$24.3M
Cap. Flow %
-11.03%
Top 10 Hldgs %
60.19%
Holding
74
New
20
Increased
14
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
HOLX
Hologic
HOLX
+$22.6M
2
SNY icon
Sanofi
SNY
+$19.6M
3
PFE icon
Pfizer
PFE
+$18.3M
4
SIBN icon
SI-BONE Inc
SIBN
+$15.6M
5
JNJ icon
Johnson & Johnson
JNJ
+$6.88M

Top Sells

Rank Stock Value
1
COR icon
Cencora
COR
+$18.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$16.2M
3
LH icon
Labcorp
LH
+$13.7M
4
ELV icon
Elevance Health
ELV
+$10.5M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.6%
2 Industrials 2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
1
Sanofi
SNY
$103B
$17.9M 8.12%
+409,961
New +$19.6M
PFE icon
2
Pfizer
PFE
$143B
$16.7M 7.55%
+537,698
New +$18.3M
HOLX
3
DELISTED
Hologic
HOLX
$16.6M 7.53%
+473,667
New +$22.6M
SIBN icon
4
SI-BONE Inc
SIBN
$788M
$15.8M 7.16%
1,322,344
+851,915
+181% +$15.6M
OXFD
5
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$15.7M 7.12%
1,695,888
+477,859
+39% +$6.68M
CI icon
6
Cigna
CI
$73.7B
$12.7M 5.74%
71,428
-9,311
-12% -$1.81M
ELV icon
7
Elevance Health
ELV
$81.5B
$9.84M 4.46%
43,351
-38,692
-47% -$10.5M
ZBH icon
8
Zimmer Biomet
ZBH
$18.2B
$9.51M 4.31%
96,919
-43,330
-31% -$5.68M
ZTS icon
9
Zoetis
ZTS
$32.4B
$8.85M 4.01%
75,222
+35,025
+87% +$4.61M
BMY icon
10
Bristol-Myers Squibb
BMY
$133B
$7.63M 3.46%
136,925
-264,509
-66% -$16.2M
BDX icon
11
Becton Dickinson
BDX
$45.6B
$7.12M 3.23%
31,775
-26,784
-46% -$6.61M
JNJ icon
12
Johnson & Johnson
JNJ
$618B
$6.36M 2.88%
+48,491
New +$6.88M
MCK icon
13
McKesson
MCK
$100B
$4.92M 2.23%
36,396
+26,000
+250% +$3.81M
RCM
14
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.41M 2%
484,801
+238,772
+97% +$2.87M
EHC icon
15
Encompass Health
EHC
$11B
$3.56M 1.61%
69,907
-135,100
-66% -$7.79M
AHCO icon
16
AdaptHealth
AHCO
$1.47B
$3.53M 1.6%
220,896
+53,038
+32% +$749K
LH icon
17
Labcorp
LH
$25B
$3.33M 1.51%
30,664
-95,098
-76% -$13.7M
PRAH
18
DELISTED
PRA Health Sciences, Inc.
PRAH
$3.22M 1.46%
38,817
-20,166
-34% -$1.97M
AVTR icon
19
Avantor
AVTR
$9.32B
$3.12M 1.41%
+249,382
New +$4M
PRTA icon
20
Prothena Corp
PRTA
$425M
$2.74M 1.24%
255,949
+145,814
+132% +$1.77M
ACRS icon
21
Aclaris Therapeutics
ACRS
$726M
$2.72M 1.23%
2,619,187
+564,118
+27% +$768K
AMGN icon
22
Amgen
AMGN
$208B
$2.67M 1.21%
+13,193
New +$2.88M
HRC
23
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$2.64M 1.2%
26,240
-39,603
-60% -$4.1M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$11.6B
$2.42M 1.1%
+28,599
New +$2.46M
TAK icon
25
Takeda Pharmaceutical
TAK
$54.6B
$2.37M 1.07%
+156,120
New +$2.83M
1
2 3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Endurant Capital Management held 74 positions worth $221M, down 30% from $317M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Endurant Capital Management withdrew a net $24.3M in Q1 2020, closing 23 positions and reducing 17 holdings. Its most notable exit was Cencora, an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Industrials.

Against the trend, Endurant Capital Management opened a new position in Hologic worth $16.6M.

  • Endurant Capital Management's largest Q1 2020 buy was Hologic: 473,667 shares worth $16.6M.
  • Endurant Capital Management added most to SI-BONE Inc in Q1 2020, an estimated $15.6M increase.
  • Endurant Capital Management's biggest Q1 2020 reduction was Bristol-Myers Squibb, cutting an estimated $16.2M.
  • Endurant Capital Management fully exited Cencora in Q1 2020, selling an estimated $18.6M.
  • Endurant Capital Management's ten largest holdings make up 60% of its $221M portfolio in Q1 2020.
  • Endurant Capital Management opened 20 new positions and closed 23 in Q1 2020.
  • Endurant Capital Management's portfolio value fell 30% quarter-over-quarter to $221M.

Based on Endurant Capital Management's 13F filing for Q1 2020, filed 15 May 2020.